TradersLink News
Small Cap News Context
Saved TradersLink press-release and filing article pages. Discord alerts can link here when full article context is available.
Published Articles
Latest saved alerts
ORIO receives Nasdaq notice for sub-$1 bid; 180 days to regain compliance
Orion Digital (ORIO) received a Nasdaq notification saying its common share bid price closed below the US$1.00 minimum for the last 30 consecutive business days, triggering a notice of deficiency but not affecting current trading. Nasdaq has given the company 180 calendar days (until December 22, 2026) to regain compliance by having the bid close at $1.00 or more for at least ten consecutive business days. The company says operations are unaffected, it will monitor options to regain compliance, and it may be eligible for an additional 180-day extension if it meets other listing requirements.
Solmate (SLMT) shareholders re-elect full board, reject RockawayX activist push
At its 2026 AGM Solmate Infrastructure (NASDAQ: SLMT) shareholders re-elected all five director nominees with support between ~61.8% and 69.3% on 71.49% turnout and ratified the company’s auditor (99.08%). The company says shareholders rebuffed RBCH/RockawayX’s control campaign, plans to pursue claims against them, and noted a derivative suit and an adjourned portion of the meeting remain outstanding.
8-K: GameStop posts FY26 outlook; no immediate GME issuance but potential dilution tied to eBay deal, awards and warrants
GME filed SEC Form 8-K. The filing identifies potential future supply pressure: a CEO performance award (dilution if vested/exercised), warrants/distributions tied to Oct 7, 2025 and the Convertible Notes (could be issued/exercised later), and possible issuance of GME common stock as part of any completed eBay acquisition; separately, the HSR condition for eBay Put/Call Pairs was satisfied on June 3, 2026 enabling physical settlement of the options (affects eBay shares, not immediate GME sellable supply).
MTNB: NYSE American accepts compliance plan; deadline Oct 2, 2027 after equity shortfall
Matinas (MTNB) received an NYSE American notice on June 24 that it is not in compliance with Sections 1003(a)(ii) and (iii) of the Company Guide because stockholders’ equity was $3.02M as of March 31, 2026 and the company has reported losses in the last five fiscal years; Matinas submitted a plan on May 4 that the exchange accepted and granted a plan period through Oct. 2, 2027, with quarterly monitoring. If Matinas fails to regain compliance by the deadline or does not make progress consistent with the plan, NYSE American staff may initiate delisting proceedings, though there is no immediate impact on listing, ongoing operations, or SEC reporting.
TEN Holdings prices 7.5M-share offering at $1.00 to raise ~$7.5M
TEN Holdings priced an underwritten registered offering of 7.5 million common shares at $1.00 per share to raise approximately $7.5 million in gross proceeds, with WestPark Capital as sole placement agent. The offering is expected to close on or about June 30, 2026, subject to customary closing conditions; net proceeds will be used for general working capital and repayment of indebtedness. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Jun 30, 2026), and once the offering closes those shares have been issued.
Catheter Precision buys 2.94M SOAR shares (7.5%) in private placement
AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Volato Group, Inc. filed SEC Form SCHEDULE 13G. Catheter Precision, Inc. acquired 2,941,176 shares of Volato Group, Inc. (NYSE American: SOAR) pursuant to a Securities Purchase Agreement, with the closing on June 18, 2026. The Schedule 13G filing reports that this equals 7.5% of the issued common stock (based on 39,336,982 shares outstanding after the placement) and states the shares are held with sole voting and dispositive power while the purchaser certifies passive intent.
TNMG receives Nasdaq delisting determination; will request hearing
TNL Mediagene (TNMG) said Nasdaq notified the company on June 22, 2026 that its shares are subject to delisting after the closing bid stayed below $1.00 for 30 consecutive business days (May 7–June 18). The company is ineligible for a typical cure period due to a recent reverse stock split and Nasdaq also cited a separate prior non-compliance with the $2.5M minimum stockholders' equity requirement. TNL will timely request a Nasdaq hearing to appeal (which automatically stays any suspension) and will present a plan to regain compliance while shares continue trading under TNMG pending the Panel's decision.
CIIT updates progress with Greypole on Zimbabwe gold/chromium evaluation and local chromium supply chain
Tianci International (CIIT) and Greypole Mining said they are progressing geological and feasibility work on a ~500-hectare prospective gold zone (including a 42-hectare priority target) in Gwanda and a ~1,500-hectare prospective chromium area in Zvishavane (core ~420 hectares across six belts). While resource delineation and mining-claims compliance continue, the partners are expanding local chromium procurement and infrastructure — leasing land, planning ~12,000 sq m of warehouses and beneficiation equipment — targeting an average supply capacity of ~10,000 tonnes of chromium products per month to boost trading volumes.
CIIT reports progress on Zimbabwe gold/chrome MOU; plans local chromium supply chain with 10,000 t/mo target
Tianci International (CIIT) says it and Greypole Mining have advanced geological sampling and feasibility work under their April MOU to evaluate a ~500-hectare gold target in Gwanda (42 ha priority) and a ~1,500-hectare chromium target in Zvishavane (core ~420 ha), while also progressing mining-claims compliance reviews. The partners are simultaneously building a localized chromium sourcing, warehousing and beneficiation network (first phase ~12,000 sq.m. warehouse, 360-ha procurement radius) aimed at supporting CIIT's trading volumes with a targeted ~10,000 tonnes/month supply capacity, though no reserves or commercial production have been announced.
HCTI agrees to issue 2.83M shares as make‑whole; multiple preferred issues convertible after shareholder approval
HEALTHCARE TRIANGLE, INC. filed SEC Form 8-K. Healthcare Triangle agreed to issue 2,828,167 common shares to SecureKloud as a make‑whole, but that issuance is conditioned on stockholder approval under Nasdaq Rule 5635(b) and will be included in the company's next resale registration (so not immediately tradeable). An amendment also provides for $12,000,000 of restricted common stock and issuance of 18,000 preferred shares (issued June 26, 2026 but not convertible until shareholder approval), with any excess over 19.99% delivered as pre‑funded warrants exercisable only after approval. The company filed a Certificate designating 23,000 shares of Series C convertible preferred (convertible at the company's option into ~9.9M common shares after shareholder approval), so there is significant potential post‑approval dilution if conversions/exercises occur.
Aterian declares CVR dividend; investor to buy 3.5M convertible preferred
Aterian, Inc. filed SEC Form 8-K. Aterian's board declared a contingent value right (CVR) dividend to holders of common stock and participating warrants of record as of July 8, 2026, with payment to be made within 60 days after the record date and no later than September 4, 2026, contingent on closing of the asset sale and securities purchase. Separately, David E. Lazar agreed to purchase 1,750,000 shares of Series AA and 1,750,000 shares of Series AAA convertible preferred (3.5M total) from the company — these are preferred shares (company-issued) that could create future common share dilution if converted, but conversion terms and timing were not disclosed. The filing estimates net proceeds available to distribute via the CVR from the transactions of roughly $10.6M–$14.2M (approximately $0.85–$1.14 per common share), though amounts are subject to adjustments, reserves and closing conditions.
HPAI H1 FY2026: Revenue +7.7% to $17.7M; swings to $1.7M loss as R&D ramps; launches HyprX/TwinX
Helport AI reported H1 FY2026 revenue of $17.7M, up 7.7% YoY, with average monthly subscribed AI Assist users rising 16.8% to 37,908 and gross profit stable at $9.1M; operating cash flow was positive ~$5.0M. The company swung to a net loss of $1.7M (vs $1.1M net income prior period) driven by a $4.3M increase in R&D and higher credit losses, while launching HyprX and TwinX, securing commercial deals (Dreame, Start Nine) and a partnership with QuickCEP that management says should support larger commercial revenue in FY2027.
HPAI H1 FY2026: Revenue +7.7% to $17.7M; launches HyprX/TwinX but posts $1.7M loss
Helport AI (HPAI) reported H1 FY2026 revenue of $17.7M, up 7.7% y/y, and average monthly subscribed users rose 16.8% to 37,908 while gross profit held at ~$9.1M; the company swung to a $1.7M net loss (vs $1.1M net income prior year) driven by higher R&D spending and increased credit losses. Management launched HyprX and TwinX, expanded multilingual delivery hubs, and secured commercial agreements (Start Nine, Dreame) plus a QuickCEP partnership to accelerate enterprise deployments, but cash on hand was only $688k despite positive operating cash flow of ~$5.0M and a decline in working capital.
Phunware grants up to 529,100-share inducement package to new CEO with $5 strike and $4.5M revenue/VWAP hurdles
Phunware granted new CEO Dmitry Kroshka a time‑vested RSU award (105,820 RSUs), performance RSUs (317,460 RSUs) and a stock option for 105,820 shares as an inducement under Nasdaq Rule 5635(c)(4), effective May 13, 2026, with board/comp committee approvals in June 2026. The performance RSUs vest only if the stock hits a $5.00 VWAP for 20 days and the company achieves $4.5M revenue (trailing 12 months, excluding professional services), so dilution is conditional and tied to sustained share price and revenue targets.
Neuphoria confirms talks with Scancell on potential acquisition; Scancell would seek Nasdaq listing
Neuphoria (NEUP) confirmed it is in discussions with London-listed Scancell about a possible acquisition/combination and said Scancell would become Nasdaq-listed if a transaction closes, but emphasized there is no certainty a deal will be reached. The company reminded investors that its lead asset BNC210 missed primary and secondary endpoints in the AFFIRM-1 Phase 3 trial and development was halted, and said it is conducting a strategic review.
GPUS: Hyperscale Data completes 48.5‑acre purchase, Michigan campus now ~83 acres
Hyperscale Data (GPUS) completed a 48.5‑acre acquisition that more than doubled its Michigan AI data center campus to approximately 83 acres, positioning the site for expanded AI colocation and Bitcoin mining operations. The company said the purchase creates a long‑term natural buffer and, together with a recently signed master services agreement, supports further buildout and customer offerings. Hyperscale also reiterated a planned divestiture of Ault Capital Group in Q2 2027 (via a Series F preferred exchange) that would refocus the company as a data center owner/operator and digital asset holder, though timing, costs and development schedules for the expansion were not disclosed.
Larimar (LRMR) schedules June 29 webcast with nomlabofusp regulatory update and long-term study data
Larimar Therapeutics (LRMR) will host an investor webcast on June 29, 2026 to provide a regulatory update and present data from its ongoing long-term open-label study of nomlabofusp for Friedreich's ataxia. The event could move expectations for BLA timing and give longer-term safety/efficacy signals, but the announcement gives no specific results, sample sizes, or firm submission dates.
Universe Pharmaceuticals (UPC) to buy Best Praise's five-patent portfolio for $10.75M paid in stock
Universe Pharmaceuticals agreed to acquire 100% of Best Praise International, which holds five Chinese patents across age-related, neurodegenerative, cognitive, cardiovascular, antibacterial and drug-delivery technologies, for US$10,751,000 to be paid as 4,376,552 Class A ordinary shares; the deal was board-approved and is expected to close in Q3 2026 subject to customary conditions. The company says the patents complement its elderly-health focus and could enable R&D, licensing or co-development opportunities, but the acquisition is share-based (dilutive) and closing, enforceability and commercial viability of the patents are not guaranteed.
EONR starts Phase 1 of up-to-92-well San Andres horizontal drilling program
EON Resources (EONR) says Phase 1 of its planned up-to-92-well San Andres horizontal program has begun after regulatory approval for the first three horizontal wells, which Virtus will operate and are slated to be drilled in July; LHO holds a 35% working interest. The company completed three vertical well recompletions to test completions, expects ~10 new horizontals by year-end 2026 and will release 2026 drilling results in Q1 2027 — any material production uplift is unproven until wells are drilled, completed and tested.
SEGG sues White Diamond and Adam Gefvert for $20M, alleges 'short-and-distort' after June 10 report
SEGG Media filed a $20 million business-disparagement lawsuit in Texas against White Diamond Research LLC and Adam Gefvert, alleging a false and misleading short-seller report published June 10 was part of a "short-and-distort" scheme that drove the company's stock down more than 50%. The company pushed back on claims it lacks operations, citing a controlling stake in Veloce Media Group, a June 10 rollout of Sports.com Predict, and said it will publish a detailed FAQ and the complaint to rebut the report and pursue legal remedies.
SEGG sues White Diamond and Adam Gefvert for $20M, blames June short-seller report for >50% stock drop
SEGG Media (SEGG; LTRYW) filed a $20 million business-disparagement lawsuit in Texas against White Diamond Research and Adam Gefvert, alleging a June 10 'short-and-distort' report contained false, misleading statements that drove the company’s stock down more than 50%. The company rebutted the report by citing completed strategic transactions (including a controlling interest in Veloce Media Group with pro forma SEC disclosure), saying its Sports.com Predict rollout began June 10, and pledged to publish a detailed FAQ and the complaint on its investor site.
VCI Global warrant exercise raises $6.87M — 880k shares at $5.62
A warrant holder exercised 880,000 VCI Global warrants at $5.62 per share, generating approximately $6.87 million of gross proceeds. The exercise appears completed, so the 880,000 new common shares are being issued (immediate dilution). The exercising party was Esousa Group Holdings and the $5.62 strike represented a 24.9% premium to VCI Global's June 24 close; E.F. Hutton served as financial advisor. Timing: Warrant exercises are already completed, so dilution is already in effect.
Cosmos Health (COSM) Signs Qatar Distribution Deal with IMC, Gets 31,000‑Unit Order
Cosmos Health announced a distribution agreement with International Medical Company (IMC) to roll out its Sky Premium Life nutraceuticals in Qatar, and IMC placed an initial purchase order for 31,000 units. IMC’s Kulud Pharmacies network (over 130 branches) will handle sales, marketing, regulatory affairs, logistics and distribution, giving Cosmos immediate nationwide retail reach as it expands into Gulf markets.
COSM signs distribution deal with Qatar's IMC; initial 31,000‑unit order for Sky Premium Life
Cosmos Health (NASDAQ: COSM) signed a distribution agreement with International Medical Company (IMC), owner of Qatar's Kulud Pharmacies, to sell its Sky Premium Life nutraceutical line in Qatar; IMC placed an initial purchase order for 31,000 units and will handle sales, regulatory, logistics and distribution. The deal gives Cosmos immediate retail access across Kulud's >130 pharmacies and supports Sky Premium Life's Gulf expansion, though the company did not disclose pricing, revenue impact or the cadence of follow-on orders.
HIVE prices US$115M 0% exchangeable senior notes due 2031 (upsized)
HIVE priced US$115 million aggregate principal of 0% exchangeable senior notes due 2031 in a private Rule 144A offering by its Bermuda subsidiary, up from $100M, with an initial purchasers' option to buy up to an additional $15M. The notes are non‑interest bearing, guaranteed by HIVE, exchangeable at 206.9429 shares per $1,000 principal (initial exchange price ≈ $4.83) and the sale is expected to close on June 30, 2026. Estimated net proceeds are ~US$110.0M (≈US$124.5M if the option is exercised) and HIVE entered capped‑call hedges (cap $8.5275) whose hedging activity could involve purchases or sales of HIVE shares. Timing: The press release does not indicate dilution today; initial share dilution occurs at the offering close (Jun 30, 2026), and once the offering closes those shares have been issued.
TRNR to implement 1-for-7 reverse split effective June 30
Interactive Strength (TRNR) will effect a 1-for-7 reverse stock split effective June 30, 2026, reducing outstanding shares from ~3.6 million to ~0.5 million and continuing to trade under the same ticker. The split is intended to help regain compliance with Nasdaq's $1.00 minimum bid requirement; outstanding equity awards and warrants will be proportionally adjusted and fractional shares will be paid in cash. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
MODD begins shipping Pivot tubeless insulin patch pump starter kits to endocrinology practices
Modular Medical (MODD) said Pivot tubeless insulin patch pump starter kits are now shipping to endocrinology offices for clinician training, and pumps will be offered to patients in the coming days and weeks. The company plans a phased commercial rollout targeting select high-volume endocrinology practices and metro markets by late 2026, aiming at adults on multiple daily injections (about 70% of insulin-dependent adults) — a large market opportunity but dependent on patient conversion and manufacturing scale.
Mobix Labs terminates equity line and deregisters ~900,000 potential shares (MOBX)
Mobix Labs (MOBX) terminated its equity line of credit and filed a post-effective amendment to deregister roughly 900,000 shares that had been registered for potential sale; those shares were never issued and will not be issued under the terminated facility. The company says the move removes a potential source of future dilution and simplifies its capital markets profile as part of disciplined capital management.
Ex‑NASA Deputy Administrator Fred Gregory joins Starfighters Space (FJET) advisory board
Starfighters Space (FJET) named retired astronaut and former NASA Deputy Administrator Frederick D. Gregory as the inaugural member of a newly formed Strategic Advisory Board. Gregory’s NASA leadership, test‑pilot background and experience flying the F‑104 (the exact aircraft FJET operates) boosts credibility as the company scales Mach‑2+ flight testing and advances its STARLAUNCH air‑launch program, but the appointment is advisory only and does not represent a contract or revenue.
RedCloud (RCT) gets perpetual India apparel/footwear dataset (~$35.05M, 300k txns) to train RedAI/RAID
RedCloud executed a perpetual Data Access & Usage Framework with a leading Indian apparel and footwear distributor granting SKU- and brand-level access to ~300,000 transactions (~$35.05M total transaction value) spanning seven years; RedCloud retains ownership of all derived data, models and outputs. The dataset will be used to train and activate RedAI’s RAID demand-forecasting engine to support commercial engagement in India, though the related annual license fee is contingent on joint-venture revenues with no guaranteed minimum.
SaverOne completes ~$7M VisionWave equity transaction to advance RF defense sensing
SaverOne and VisionWave have completed a strategic transaction first announced in January 2026, with SaverOne receiving roughly $7 million of VisionWave common stock as consideration. The deal formalizes a collaboration to integrate SaverOne’s RF sensing (demonstrated to detect wireless activity in limited-visibility and non-line-of-sight scenarios) into VisionWave’s autonomous/RF imaging platform for defense, homeland security and critical infrastructure use cases.
SHPH subsidiary United Dogecoin buys DG1+ miners and secures hydroelectric site at $0.064/kWh; miners due ~60 days
Shuttle Pharmaceuticals' newly acquired United Dogecoin purchased a fleet of ElphaPex DG1+ Scrypt miners (14.4 GH/s per unit) and secured a renewable hydroelectric data-centre site with power priced at $0.064/kWh, with deployment expected in about 60 days. The moves establish low-cost, renewable-powered mining capacity and mark United Dogecoin's planned entry into Dogecoin network mining, though the timeline and "largest by hashrate" ambition are forward-looking and depend on delivery, installation and operational execution.
HCWB to do 1-for-6 reverse split effective June 30 to meet Nasdaq $1 bid rule
HCW Biologics (HCWB) will effect a 1-for-6 reverse stock split at 12:01 a.m. ET on June 30, 2026, reducing shares outstanding from ~9.58M to ~1.60M (new CUSIP 40423R303) and will continue trading under the HCWB symbol on Nasdaq. The split is intended to ensure compliance with Nasdaq’s $1 minimum bid-price rule and conditions set by a Nasdaq Hearings Panel (the company completed at least 20 trading days above $1 and reported 28 consecutive days above $1), and the company warns failure to maintain the bid will risk immediate delisting; no fractional shares will be issued—holders otherwise due fractions will receive one whole share.
Life Sciences Virtual Investor Forum presentations now on-demand; LABT among presenters
Presentations from the June 24–25 Life Sciences Virtual Investor Forum are now available on-demand and will be accessible 24/7 for 90 days, with investor download materials and (limited) 1x1 meeting requests noted. Presenting companies include a broad slate of small-cap life sciences and medtech tickers — including LABT, CTSO, PHIO and ATYR — but the release doesn't include new clinical data or company-specific material announcements.
Life Sciences Virtual Investor Forum presentations available on-demand
Virtual Investor Conferences posted on-demand recordings and downloadable investor materials from the June 24-25 Life Sciences Virtual Investor Forum; recordings are available 24/7 for 90 days. Presenting companies include IMUNON (IMNN) and ~25 other life-sciences tickers and some were offering 1x1 management meetings (deadline listed as June 19), but the release contains no new clinical or financial results.
ROLR wins NFA introducing-broker registration under Crypto.com FCM guarantee to advance U.S. prediction markets launch
High Roller’s subsidiary ROLR US LLC was approved as a member of the National Futures Association and registered as a guaranteed introducing broker under a guarantee agreement with OG/Crypto.com FCM, which will carry customer accounts and provide clearing, custody and transaction processing while ROLR will not hold customer funds. This clears a key regulatory hurdle toward a planned U.S. commercial launch of the ROLR prediction markets platform, with eligible customers to access CDNA-offered prediction contracts (sports, finance, entertainment) and an initial 24-month exclusivity and revenue-sharing arrangement; launch remains subject to final integration, testing and compliance.
BTCT private placement: 6.14M units for ~$7M upfront; 2 warrants/unit could add ~$21M
BTC Digital agreed to sell 6,140,350 Common Units (or Pre‑Funded Units) at $1.14 per unit in a private placement to raise approximately $7.0M upfront; each unit includes two PIPE common warrants exercisable at $1.71 (if fully exercised those warrants could provide ~ $21M additional proceeds). The transaction is expected to close on or about June 29, 2026 (dilution delayed until closing); pre‑funded warrants are immediately exercisable and the common warrants are exercisable upon issuance and expire in 60 months. Timing: Public-market dilution depends on another filing or resale step first, and the press release does not say when that will be completed.
FBLG to sell ~4.08M shares + warrants in $3.0M at‑the‑market private placement (up to $9.0M)
FibroBiologics (FBLG) agreed to sell an aggregate of 4,081,633 shares of common stock (or pre‑funded warrants in lieu) together with Series A and short‑term Series B warrants in a private placement priced at‑the‑market at $0.735 per share, expected to raise approximately $3.0M upfront and up to an additional ~$6.0M if warrants are fully exercised (total potential $9.0M). The offering is expected to close on or about June 29, 2026; the warrants are exercisable only after the company obtains the required stockholder approval and the resale registration is effective, so initial dilution occurs at closing for the issued shares/prefunded warrants while further dilution from warrant exercises is delayed pending approval and exercise. Timing: Dilution depends on stockholder approval first, and the press release does not say when that will happen.
WGRX proposes rename to DataMeds AI (proposed ticker MEDS), rebrands pharmacy unit and targets Q3 2026 closing
Wellgistics Health (NASDAQ: WGRX) said its board selected DataMeds AI, Inc. as the proposed new corporate name (proposed ticker MEDS) and filed a preliminary proxy with the SEC seeking shareholder approval; it also will rebrand its Pharmacy division as Corexa Health while pursuing a proposed transaction with DataVault AI, Scilex, EOS and HealthBridge aimed at vertically integrating telemedicine, pharmacy, labs and wearables, targeted for completion in Q3 2026 subject to customary closing conditions. The company reports 2,647,198 common shares outstanding with ~1,333,930 shares locked up for at least 90 days, 919,465 shares deposited at DTCC available for trading, 80,826 cash warrants outstanding at a $35 strike, and no convertible debt or preferred equity currently eligible to convert to free-trading common shares.
reAlpha (AIRE) launches flat-fee mortgage comp model with RSUs and uncapped recruiting pay
ReAlpha Mortgage rolled out a flat fee compensation model for loan originators that replaces tiered splits with a simpler fee structure, makes qualifying originators eligible for restricted stock units (RSUs), and offers uncapped recruiting income for bringing other originators onto the platform. The company says the plan, paired with its AI engagement tools and integrated realty/mortgage/title ecosystem, is designed to accelerate national LO recruitment and scale originations as the broker channel grows.
CDT highlights Sarborg's quantum-assisted coformer selection for solid-form development
CDT flagged Sarborg's expansion of its Signature Intelligence platform into quantum-assisted coformer selection via SarborgQ, combining proprietary datasets, agentic AI and emerging quantum computing to accelerate solid-form work. Sarborg says it has a curated database of >850 coformers and intends to deploy the tools to identify new co-crystal/salt opportunities, create patentable assets across its IP portfolio and offer the capability to external partners, though no validation data or timelines were disclosed.
Maris‑Tech wins ~$350k government prime contract to supply MIL‑STD vehicle audio system
Maris‑Tech (MTEK, MTEKW) was awarded a government defense prime contract to develop and supply a MIL‑STD vehicle‑mounted audio system for armored fighting vehicles, with aggregate orders of approximately $350,000 expected to be delivered by year‑end 2026. The deal is the company's first as a prime contractor and expands its portfolio beyond edge video and AI into battlefield audio systems, though the disclosed value is modest and the end customer is unnamed.
MTEK wins ~$350K gov't contract as prime to supply MIL‑STD vehicle-mounted audio system
Maris‑Tech (MTEK / MTEKW) said it was awarded a government defense contract as prime contractor to develop and supply a MIL‑STD vehicle‑mounted audio-based system for armored fighting vehicles, with orders totaling roughly $350,000. Deliveries are expected by the end of 2026; the system will support live and pre-recorded audio distribution and marks the company's move beyond edge video/AI into complementary battlefield audio systems.
Cineverse (CNVS) Q4 revenue +67% to $26M as Giant and IndiCue add $11.6M; reaffirms FY27 $115–120M guidance
Cineverse (CNVS) reported Q4 FY2026 revenue of $26.0M, up 67% YoY, driven by $11.6M in advertising technology and media services revenue from newly closed acquisitions IndiCue and Giant Worldwide; Q4 net income attributable to common was $1.1M (including a $4.3M non‑cash bargain purchase gain) and Adjusted EBITDA was roughly $0.1M as M&A integration and marketing weighed on margins. Full‑year revenue fell 16% to $65.7M and the company posted a FY net loss of $(9.2)M (Adjusted EBITDA $(3.4)M), but management reaffirmed fiscal 2027 guidance of $115–120M revenue and $10–20M Adjusted EBITDA, expects the acquisitions to contribute >$50M in FY27, and targets about $10M of annualized cost reductions/synergies.
SHPH unit buys DG1+ Dogecoin miners and secures hydro site at $0.064/kWh; rigs due in ~60 days
United Dogecoin, recently acquired by Shuttle Pharmaceutical (NASDAQ: SHPH), purchased a fleet of ElphaPex DG1+ Scrypt miners (14.4 GH/s each) and expects to deploy them and be operational in about 60 days, subject to delivery and installation timelines. The company also secured a hydroelectric-powered site at a contracted rate of $0.064 per kWh, aiming to use low-cost renewable power to scale Dogecoin mining and pursue leadership by hashrate.
FDA accepts Replimune RP1 BLA resubmission for advanced melanoma; PDUFA Aug 2
The FDA has accepted for review Replimune's resubmitted Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma, classifying it as a complete Class 1 response with a target action date of August 2, 2026 and an advisory committee expected in late July. The resubmission seeks accelerated approval based on IGNYTE trial data in patients who progressed on anti‑PD‑1 therapy; the company did not disclose efficacy or safety numbers in this release, so near‑term market reaction will hinge on the advisory committee and FDA review.
Study finds mannose-rich extracellular vesicles elevated in Long COVID and captured by Hemopurifier's GNA resin
Aethlon announced a peer‑reviewed study showing Long COVID patients had ~2x higher levels of mannosylated extracellular vesicles (EVs) versus recovered individuals and that those mannose‑positive EVs can be bound by Galanthus nivalis agglutinin (GNA) affinity resin—the active capture component of the Hemopurifier. The study (using plasma from UCSF's LIINC cohort) also showed GNA resin reduced seven circulating microRNAs linked to immune/inflammatory pathways, providing translational rationale to test whether Hemopurifier removal of disease‑associated EVs could be a therapeutic approach, though no clinical benefit has yet been demonstrated and the company remains focused on its oncology trial.
IPST: Story Foundation rebrands to DATA Foundation; DATA Network & Trace launch, $IP -> $DATA token migration
IP Strategy (IPST) highlighted Story Foundation’s rebrand to The DATA Foundation and the launch of DATA Network, Trace, Poseidon and contributor app Numo, plus an announced integration with Kled that has begun registering 1.5 billion user-contributed records onchain. IP Strategy, which holds $DATA (formerly $IP) as its primary reserve and runs validator infrastructure, says the moves reinforce its thesis that programmable IP and auditable AI training-data infrastructure could drive long-term utility; the $IP token will convert to $DATA 1:1 with no action required by holders.
Quantum Cyber hires bankers to pursue equity stake in SpaceX
Quantum Cyber (QUCY) said its board approved engaging investment banking advisors to facilitate acquiring an equity stake in SpaceX and would carry any stake as a strategic technology holding on its balance sheet. The company said SpaceX’s LEO communications, space-based sensing and defense work complement Quantum Cyber’s AI/quantum autonomous defense platform and noted the move follows a June 11 IP license deal, but provided no terms, timing, or guarantee the stake can be sourced or acquired.
Ensysce enrolls first patient in final stage of PF614‑MPAR‑102 trial
Ensysce (ENSC) announced first-patient enrollment in Part 3 (final stage) of its PF614‑MPAR‑102 study evaluating PF614‑MPAR, an opioid engineered with a built‑in chemical “safety switch” to limit additional drug release and protect against oral overdose. The program has FDA Breakthrough Therapy designation and NIDA support; prior data showed maintained therapeutic plasma levels at normal doses and blunted exposure at supratherapeutic doses, and Part 3 will test the protective profile across a broader range of dosing scenarios.
Ticker Pages